Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.82 USD
Change Today +0.12 / 1.38%
Volume 603.1K
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting

ImmunoGen, Inc. provided information on ImmunoGen-related presentations to take place at the 2015 American Society of Clinical Oncology (ASCO) annual meeting being held May 29-June 2 in Chicago, IL. ImmunoGen’s mirvetuximab soravtansine is the first ADC to target folate receptor alpha (FRa), which is highly expressed on many ovarian cancers and on other types of solid tumors. The ASCO presentations will be on the initial findings from the Phase I expansion cohort assessing this ADC as a single agent for the treatment of patients with FRa-positive platinum-resistant ovarian cancer (abstract #5518) and the dose-finding results to date with a weekly dosing schedule compared with a once every three week schedule (abstract #5558). Abstract #5518: Title: “Preliminary single agent activity of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. Gynecologic Cancer Poster Session: May 30, 1:15-4:45pm CT (S Hall A, Board #76), followed by oral discussion with highlights during the Gynecologic Cancer Poster Discussion Session 4:45-6:00pm CT (E354b). Abstract #5558: Title: Phase 1 study of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. Gynecologic Cancer Poster Session: May 30, 1:15-4:45pm CT (S Hall A, Board #116). There will be several presentations on Roche’s Kadcyla® (ado-trastuzumab emtansine), which uses ImmunoGen’s ADC technology, including one on the data from the MARIANNE Phase III trial (Abstract #507). Title: “Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. Breast Cancer Oral Abstract Session: June 1, 10:12-10:24am CT (N Hall B1).

ImmunoGen, Inc. Presents at Jefferies 2015 Global Technology, Media and Telecom Conference, May-11-2015

ImmunoGen, Inc. Presents at Jefferies 2015 Global Technology, Media and Telecom Conference, May-11-2015 . Venue: Mandarin Oriental Brickell, Miami, Florida, United States.

ImmunoGen, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 09:10 AM

ImmunoGen, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 09:10 AM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Carol Hausner, Executive Director of Investor Relations & Corporate Communications, Charles Q. Morris, Chief Development Officer and Executive Vice President.

ImmunoGen, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Revises Earnings Guidance for the Year Ending June 30, 2015

ImmunoGen, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported a net loss of $21.6 million, or $0.25 per basic and diluted share, compared to a net loss of $37.5 million, or $0.44 per basic and diluted share, for the same quarter last year. Revenues for the quarter were $11.4 million, compared to $6.9 million for the same period last year. The current period includes a $5.1 million of revenue from license and milestone fees, just principally a $5 million cash milestone payment earned from Novartis. Loss from operations was $21.2 million compared with $37.4 million a year ago. For the nine months, the company's total revenues were $72.9 million compared with $54.2 million a year ago. Loss from operations was $29.4 million compared with $45.0 million a year ago. Net loss was $30.3 million or $0.35 per basic and diluted share compared with $44.9 million or $0.53 per basic and diluted share a year ago. Cash used in operations was $27.4 million in the period and capital expenditures were $4.5 million. The company has updated its guidance for its fiscal year ending June 30, 2015. The company's guidance for its net loss is unchanged, and expected to be between $60 million and $65 million. Expected revenues are now projected to be between $85 million and $95 million, compared with previous guidance of between $100 million and $105 million, due to changes in the expected timing of partner milestone events. The company's guidance for cash used in operations and capital expenditures remains unchanged from that issued on January 2015. These are projected to be between $55 million and $60 million and between $7 million and $9 million, respectively.

ImmunoGen, Inc. Appoints Anna Berkenblit as Vice President and Chief Medical Officer

ImmunoGen, Inc. announced the appointment of Anna Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer. Dr. Berkenblit reports to Dr. Charles Morris, EVP and Chief Development Officer and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. Dr. Berkenblit has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $8.82 USD +0.12

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.56 EUR +0.355
Abzena PLC 83.50 GBp +0.50
BioInvent International AB kr2.13 SEK +0.01
Kyowa Hakko Kirin Co Ltd ¥1,662 JPY -23.00
MorphoSys AG €68.47 EUR +0.472
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book 12.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.